A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.

A Phase I, open-label, first-in-human study to determine the MTD, recommended phase 2 dose (RP2D), assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of LXP1788 Injection in patients with advanced solid tumor. Patients with advanced solid tumors that are refractory to currently available therapies or for whom no effective treatment is available will be selected. The main questions it aims to answer are: 1. To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of LXP1788 Injection 2. To evaluate the pharmacokinetics (PK) of L

Trial Details

NCT ID
NCT06883539
Phase
PHASE1
Sponsor
LaunXP Biomedical Co., Ltd.
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • LXP1788 is administered intravenously via Port-A
Locations (sample)
  • Taichung, Taiwan|24.1469,120.6839
  • Tainan, Taiwan|22.99083,120.21333

Key Eligibility Criteria

  • Written (signed) Informed Consent.
  • Male or female ≥ 18 years old.
  • Life expectancy \> 8 weeks.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →